Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 18;33(3):ar26. doi: 10.1091/mbc.E21-06-0309

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Hasegawa et al. “ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society for Cell Biology.

This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial-Share Alike 4.0 International Creative Commons License.

PMC Copyright notice

FIGURE 1: — PIKfyve inhibition does not suppress mTORC1 activity. (A) HeLa cells treated with the indicated drugs (or DMSO vehicle control) were cultured for 2 h in the growth medium or HBSS for 2 h and then analyzed by immunoblot using the indicated antibodies. (B) Quantitation of phospho-S6K1 signal intensities from immunoblots in A, following normalization to the total S6K1 protein (mean ± SD; three independent experiments). **P < 0.01. (C) HeLa cells treated with apilimod were cultured for 2 h in the indicated medium (FBS[+], 10% FBS-DMEM; FBS[-], DMEM; HBSS) and then analyzed by immunoblot using anti-phospho-S6K1 and anti-S6K1 antibodies. Representative immunoblot from three independent experiments.